The PPARgamma-activator rosiglitazone does not alter remodeling but increases mortality in rats post-myocardial infarction.

Journal article

OBJECTIVE: Peroxisome proliferator-activated receptor gamma (PPARgamma) activators may be beneficial in heart failure due to their metabolic and antihypertrophic effects, but these agents can cause oedema. We hypothesized that, on balance, the PPARgamma activator rosiglitazone would be beneficial in heart failure post-myocardial infarction. METHODS AND RESULTS: Rosiglitazone (3 mg/kg/day p.o.) given to male Wistar rats for 14 days, caused a 31% increase in left ventricular (LV) dP/dt(max) (P&...

Expand abstract

Authors: Lygate, C; Hulbert, K; Monfared, M; Cole, M; Clarke, K

• Publication status: Published
• Journal: Cardiovascular research
• Volume: 58
• Issue: 3
• Pages: 632-637
• Publication date: 2003-06-01
• DOI: 10.1016/s0008-6363(03)00289-x
• EISSN: 1755-3245
• ISSN: 0008-6363
• Language: English
• Keywords: Treatment Failure; Heart Failure; Ventricular Remodeling; Drug Therapy, Combination; Male; Thiazolidinediones; Rats; Receptors, Cytoplasmic and Nuclear; Myocardial Infarction; Angiotensin-Converting Enzyme Inhibitors; Rats, Wistar; Animals; Captopril; Cardiotonic Agents; Transcription Factors; Echocardiography